Advertisement
Screener

Exelixis Inc (EXEL) Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest

Exelixis Inc Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest

Exelixis Inc (EXEL) reported Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest of $147.60 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-21.

Discontinued › Income Statement › Unrealized Gains

us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest · last filed 2013-02-21

  • Exelixis Inc comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2012 was $147.60M.
  • Exelixis Inc comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2011 was -$75.55M, a 181.70% decline from fiscal 2010.
  • Exelixis Inc comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2010 was $92.47M, a 2032.19% increase from fiscal 2009.
  • Exelixis Inc comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2009 was $4.34M.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 12 month
2012-12-31$147.60M
10-K · filed 2013-02-21
2011-12-31-$75.55M
10-K · filed 2013-02-21
2010-12-31$92.47M
10-K · filed 2013-02-21
2009-12-31$4.34M
10-K · filed 2012-02-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Immunovant, Inc. (IMVT)United States$7.028B-14.78